Pharosity Consulting Inc

Building a Pre-Launch Gross-to-Net (GTN) Model is Essential for Pharma Success. In the pharmaceutical industry, launching a product requires precise financial planning—starting with a robust GTN model. A pre-launch GTN model not only helps forecast revenue accurately but also prepares a company to navigate complex market dynamics, including customer discounting, the setting and evolution of WAC pricing, government pricing projections, and varying customer economics. Creating this model early provides your team with scenario modeling for various go-to-market options, and therefore the ability to:? ?? Predict net revenue with greater accuracy by understanding the projected deductions by channel related to any given scenario.? ?? Optimize pricing and discount strategies to stay competitive and compliant.? ?? Align cross-functional stakeholders on financial expectations and resource allocation. A proactive GTN model mitigates risks and sets the foundation for a successful product launch, ultimately ensuring sustainable growth in an increasingly competitive market. Start building a strong foundation for your next product launch now! Connect with us to discuss how a pre-launch GTN model can drive financial success for your team. Visit Pharosity.com/contact

Doing the math and the operational planning early is the key to success. Talk to our experts!

The Intensive Road to Market: Pre-Launch Essentials for Emerging Pharma Companies Emerging pharmaceutical companies often underestimate the extensive preparation required before a drug launch. Effective pre-launch activities can start as early as 18-to-24 months prior to the market debut. Delaying this crucial groundwork can lead to missteps, gaps and even financial penalties that can have a significant impact on revenue once the drug is introduced. Read the full blog: https://lnkd.in/gtDPcuYh Request a free consultation today at https://lnkd.in/gSW4MMxN

How is your company forecasting demand? Trending based on syndicated data? Projecting new patient starts and forecasting based on persistency assumptions? Modeling and applying market events??All of these? With our deep experience, we can help you evaluate your current approach, start fresh, and even explore advanced algorithms. Contact us for a free consultation. DM us or visit pharosity.com/contact

Constructing a Pre-Launch Gross-to-Net (GTN) Model to Evaluate Go-To-Market Scenarios? Constructing a GTN model for a pre-launch product is a challenging activity for pharmaceutical manufacturers due to a frequent dearth of input data. While these models are critical to making sound strategic decisions, manufacturers need to have good answers to fill in key inputs like: ?? With what WAC price should we launch, and how often should the WAC price change? ?? What is the estimated in-market demand for the product relative to our expected ex-factory sales projection? ?? What is the channel and payer mix, the associated volume for each, and the discount approach and level offered across the channels? ?? How will projected volume and discounts impact government pricing for programs such as Medicaid, 340B, Medicare, Federal Supply Schedule, and Tricare? Pharmaceutical manufacturers typically rely on analog data from third-party sources, market research or just informed assumptions as inputs, but knowing what approach works well under different circumstances can be invaluable. And since the combination of inputs will change over time, a Pre-Launch GTN Model capable of recording scenarios is a must. Pharosity Consulting has implemented Pre-Launch GTN Models for a wide variety of pharmaceutical manufacturers, enabling them to conduct scenario modeling to evaluate the impact of strategic options on profitability. We can do that for your team as well. To learn more, visit pharosity.com/contact for a free consultation.?

Last week in Episode 2 of our Phorward Thinking webinar series, Brian Barbash, Kevin Ward and @John Ly discussed how organizations can unlock value in their data. The key takeaways are: ?? Manufacturers need to use their business questions to guide the approach for sourcing, consolidating, aggregating, and delivering data ?? Unlocking value is more than just a technology solution and must incorporate business processes, organizational alignment, and overall governance, and that ?? These opportunities are available to manufacturers of all sizes and can be achieved with budgets both large and small. We have decades of experience unlocking the value of data for manufacturers. Talking to us does not require a project.? DM us or visit pharosity.com/contact if you’d like to connect.?

There is no universal solution for manufacturers navigating the complexities of managing, collecting, and analyzing data for Gross-to-Net (GTN) forecasting and analytics. While common challenges exist, each manufacturer faces unique circumstances and specific obstacles. Inconsistent methodologies, limited access to data, and a lack of cross-functional collaboration erode trust in analytics and slow down decision-making. Critical strategic initiatives—such as pricing optimization, market access strategies, and profitability analysis—depend on accurate and consistent data. Without a shared and trusted source of truth, stakeholders risk making decisions based on incomplete or conflicting information, potentially leading to suboptimal financial performance or compliance issues. To mitigate data challenges, pharmaceutical manufacturers should consider investing in:? ?? Centralized Data Repositories: Implementing integrated platforms that consolidate data, not reports, from all departments at the lowest level of detail needed to support GTN analytics. There are many options for manufacturers with budgets large and small.? ?? Data Governance Frameworks: Establishing policies and standards to ensure consistency, accuracy, and accountability for data management.? ?? Collaborative Ownership Models: Encouraging cross-departmental collaboration to define and agree on a unified source of truth for critical datasets within GTN.? ?? Advanced Tools and Automation: Using automation and advanced analytics tools to streamline reconciliation and ensure consistency across datasets. For a free consultation, visit pharosity.com/contact today.

Don't miss out! Register now at https://lnkd.in/guZPHnc8

The feedback we received through our survey identified time collecting data as the most significant data challenge when performing Gross-to-Net (GTN) forecasting or accrual analysis.? As the pharmaceutical industry continues to face mounting financial pressure with their GTN from multiple stakeholders, organizations increasingly depend on sophisticated analysts to deliver insights that inform strategy, optimize performance, and accelerate data-driven decision-making. However, a persistent challenge lies in the disproportionate amount of time analysts devote to collecting data instead of analyzing it. This imbalance compromises the core objective of data analysis: uncovering actionable insights that drive impactful decisions.? ? What factors are contributing to the significant time spent on data collection in our industry?? ? Fragmented Data Sources? Many organizations store data across multiple systems that lack seamless integration. Analysts often spend hours retrieving, cleaning, and standardizing data before it is even ready for analysis. Multiple Data Owners? Data is often owned by different departments, such as finance, accounting, market access, marketing, or operations. Each owner has unique perspectives, priorities, and methodologies, leading to inconsistencies in how data is maintained and shared.? ? Interpretation of Individual Data Sets? Even when data is accessible, individual datasets often carry implicit assumptions or business specific interpretations that can vary across departments. Misalignment in definitions and interpretations can lead to confusion and require additional effort to reconcile and standardize. The Complexity of GTN Analysis? GTN analysis involves navigating intricate pricing strategies, discounts, rebates, and returns across multiple channels and stakeholders. The process is data-intensive and requires reconciling datasets owned by different teams, further compounding the challenges of collecting and consolidating data.? Leverage the experience of the Pharosity team. Contact us for a free consultation. You do not need an active project to benefit from our industry insights. Visit pharosity.com/contact.

Join us for the first Phorward Thinking Webinar of the year. Register today at https://lnkd.in/guZPHnc8